Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apollo: Tislelizumab Boost in ctDNA+ TNBC
NCT04501523Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Aug 2020
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen Memorial Hospital. Started Aug 2020; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04501523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04501523.